| Literature DB >> 1893647 |
Abstract
Benazepril, a newer angiotensin-converting enzyme inhibitor, has been evaluated for the treatment of mild to moderate hypertension in patients 55 years of age and older. The results of the clinical trials conducted to date indicate that benazepril provides effective antihypertensive therapy in this population, with efficacy comparable to that demonstrated in younger patients. Benazepril does not produce precipitous decreases in diastolic blood pressure following the initial dose, and is well tolerated by the elderly. It has a safety profile similar to that of placebo and generally better than that of hydrochlorothiazide.Entities:
Mesh:
Substances:
Year: 1991 PMID: 1893647 DOI: 10.1002/clc.4960141813
Source DB: PubMed Journal: Clin Cardiol ISSN: 0160-9289 Impact factor: 2.882